Cullinan Therapeutics, Inc.
CGEM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | 0.01 | -0.02 | -0.43 |
| FCF Yield | -22.19% | -31.80% | -26.82% | -6.44% |
| EV / EBITDA | -3.43 | -1.72 | 2.15 | -9.18 |
| Quality | ||||
| ROIC | -33.26% | -38.16% | -17.65% | -15.97% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 99.72% |
| Cash Conversion Ratio | 0.87 | 0.88 | -1.16 | 0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | – | – |
| Free Cash Flow Growth | -8.05% | -5.23% | -190.30% | -47.81% |
| Safety | ||||
| Net Debt / EBITDA | 0.48 | 0.50 | -1.00 | 0.88 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -0.06 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,006.31 | -9,293.37 | -10,439.78 | -21,824.25 |